Pharmaceutical

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

TYRA-200 is under clinical development by Tyra Biosciences and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma).

Jun 20, 2024 - 04:00
TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
TYRA-200 is under clinical development by Tyra Biosciences and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma).
Read the original article

Tags:

Previous Article

SGNB-7H4V by Pfizer for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of App...

Next Article

EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

How pharmaceutical firms are making their supply chains more efficient

How pharmaceutical firms are making their supply chains...

May 6, 2023

HH-006 by Huahui Health for Hepatitis D: Likelihood of Approval

HH-006 by Huahui Health for Hepatitis D: Likelihood of ...

Jan 9, 2024

Johnson & Johnson submits sNDA for SPRAVATO to treat depression

Johnson & Johnson submits sNDA for SPRAVATO to treat de...

Jul 24, 2024